ARTICLE | Clinical News
Organoselenium: Phase II start
April 16, 2007 7:00 AM UTC
Next quarter, ALT will start a Phase II trial in diabetic patients expressing the Haptoglobin 2-2 genotype. The company got an exclusive license to ALT-2074 from OXIS last week. ...